All In Biotech

Free tool

FAERS Monitor: Imuldosa

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761364 or its brand name (Imuldosa, Ustekinumab-Srlf). Reports on generic versions are filed under their own applications.

Reports

2

Serious

2

100% of reports

Hospitalization

0

Death reported

0

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • colitis ulcerative1
  • ear infection staphylococcal1
  • ear pain1
  • fatigue1
  • groin abscess1
  • hypoacusis1
  • malaise1
  • middle ear effusion1
  • oral mucosal blistering1
  • periodontitis1
  • psoriasis1
  • skin fissures1
  • social problem1
  • subcutaneous abscess1
  • tinnitus1

Reports by year received

View as table
YearReports
20251
20261

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,157 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
ear infection staphylococcal187000.621511.321,571
groin abscess18936.42232.32,231
periodontitis14857.91214.11,213
middle ear effusion14769.91192.21,191
social problem12540.9635.3634
subcutaneous abscess12194.5548.7548
oral mucosal blistering11645.6411.5410
ear pain1541.1135.3134
skin fissures1538.2134.6134
hypoacusis1244.361.160
colitis ulcerative1235.358.858
tinnitus1228.957.356
psoriasis180.520.119
malaise124.06.05
fatigue113.53.43

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.